Optimizing economic outcomes in acute exacerbations of chronic bronchitis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The treatment of community-acquired respiratory tract infections, such as acute exacerbations of chronic bronchitis (AECB), constitutes a huge socioeconomic burden. In most cases, an antimicrobial agent is advocated to lessen morbidity and prevent serious clinical sequelae. Use of antimicrobial agents for AECB, however, is controversial, as it is difficult to distinguish between bacterial and nonbacterial AECB, and only marginal benefits have been reported. Antimicrobial agents, however, have reduced relapse rates, prolonged the time between exacerbations, shortened the duration of symptoms, and reduced the need for hospitalization. Microbiologic resistance and individual patient characteristics play important roles in determining the most appropriate antimicrobial agent for patients with AECB. More research on the effect of resistant bacteria on antimicrobial response rates will enable physicians to prescribe economically rational antimicrobial therapy for this common infection.

Original languageEnglish
JournalPharmacotherapy
Volume22
Issue number1 II
StatePublished - 2002

Fingerprint

Chronic Bronchitis
Anti-Infective Agents
Economics
Community-Acquired Infections
Respiratory Tract Infections
Hospitalization
Morbidity
Bacteria
Physicians
Recurrence
Therapeutics
Infection
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Optimizing economic outcomes in acute exacerbations of chronic bronchitis. / Destache, Christopher J.

In: Pharmacotherapy, Vol. 22, No. 1 II, 2002.

Research output: Contribution to journalArticle

@article{d7c7a2d5f6b049519df7437623fa622a,
title = "Optimizing economic outcomes in acute exacerbations of chronic bronchitis",
abstract = "The treatment of community-acquired respiratory tract infections, such as acute exacerbations of chronic bronchitis (AECB), constitutes a huge socioeconomic burden. In most cases, an antimicrobial agent is advocated to lessen morbidity and prevent serious clinical sequelae. Use of antimicrobial agents for AECB, however, is controversial, as it is difficult to distinguish between bacterial and nonbacterial AECB, and only marginal benefits have been reported. Antimicrobial agents, however, have reduced relapse rates, prolonged the time between exacerbations, shortened the duration of symptoms, and reduced the need for hospitalization. Microbiologic resistance and individual patient characteristics play important roles in determining the most appropriate antimicrobial agent for patients with AECB. More research on the effect of resistant bacteria on antimicrobial response rates will enable physicians to prescribe economically rational antimicrobial therapy for this common infection.",
author = "Destache, {Christopher J.}",
year = "2002",
language = "English",
volume = "22",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1 II",

}

TY - JOUR

T1 - Optimizing economic outcomes in acute exacerbations of chronic bronchitis

AU - Destache, Christopher J.

PY - 2002

Y1 - 2002

N2 - The treatment of community-acquired respiratory tract infections, such as acute exacerbations of chronic bronchitis (AECB), constitutes a huge socioeconomic burden. In most cases, an antimicrobial agent is advocated to lessen morbidity and prevent serious clinical sequelae. Use of antimicrobial agents for AECB, however, is controversial, as it is difficult to distinguish between bacterial and nonbacterial AECB, and only marginal benefits have been reported. Antimicrobial agents, however, have reduced relapse rates, prolonged the time between exacerbations, shortened the duration of symptoms, and reduced the need for hospitalization. Microbiologic resistance and individual patient characteristics play important roles in determining the most appropriate antimicrobial agent for patients with AECB. More research on the effect of resistant bacteria on antimicrobial response rates will enable physicians to prescribe economically rational antimicrobial therapy for this common infection.

AB - The treatment of community-acquired respiratory tract infections, such as acute exacerbations of chronic bronchitis (AECB), constitutes a huge socioeconomic burden. In most cases, an antimicrobial agent is advocated to lessen morbidity and prevent serious clinical sequelae. Use of antimicrobial agents for AECB, however, is controversial, as it is difficult to distinguish between bacterial and nonbacterial AECB, and only marginal benefits have been reported. Antimicrobial agents, however, have reduced relapse rates, prolonged the time between exacerbations, shortened the duration of symptoms, and reduced the need for hospitalization. Microbiologic resistance and individual patient characteristics play important roles in determining the most appropriate antimicrobial agent for patients with AECB. More research on the effect of resistant bacteria on antimicrobial response rates will enable physicians to prescribe economically rational antimicrobial therapy for this common infection.

UR - http://www.scopus.com/inward/record.url?scp=0036137493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036137493&partnerID=8YFLogxK

M3 - Article

C2 - 11791624

AN - SCOPUS:0036137493

VL - 22

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1 II

ER -